igf 1 lr3 minimize side effects A Medical Review of IGF-1 Dosage, and Safety Aspects IGF-1 LR3 Injections: Growth &

Disclosures: Paulo Bittencourt: Nothing to Disclose, Vivian Rotman: Nothing to Disclose, Lvia Geovana Celestino: Nothing to Disclose, Antonio Ricardo Andrade: Nothing to Disclose, Liana Codes: Nothing to Disclose, Raimundo Gama: Nothing to Disclose, Raymundo Parana: Nothing to Disclose, Larissa Athayde Costa: Nothing to Disclose, Maria Ferraz: Nothing to Disclose, Gilda Porta: Nothing to Disclose 2534 THROMBOCYTOPENIA PREDICTS THE LONG-TERM LIVER OUTCOMES IN WILSON'S DISEASE Chien-Ting Hsu 1 Sung-Pin Fan 2 Jia-Feng Wu 2 Tung-Hung Su 2 Tai-Chung Tseng 2 Chin-Hsien Lin 2 Mei-Hwei Chang 3 Huey-Ling Chen 3 Yen-Hsuan Ni 3 , 1 National Taiwan University BioMedical Park Hospital, 2 National Taiwan University Hospital, 3 National Taiwan University Background: Wilson's disease (WD) is a rare autosomal recessive genetic disorder of copper metabolism caused by ATP7B gene mutations

PMID: 34209583

Studies administering 3 gm/day to 6 gm thrice daily over 1 to 24 months reported significant improvements, corroborated by recent trials with doses up to 2 gm/day without adverse effects

GPx7 is known as a nonselenium cysteine due to its homology with GPx4